Literature DB >> 1363165

The relationship between anti-human eye muscle antibodies and thyroid function, anti-TSH receptor antibodies and eye symptoms in Graves' ophthalmopathy.

I Molnár1, C Balázs.   

Abstract

Circulating IgG, IgA, and IgM antibodies to human eye muscle cytosol antigens were studied in 60 patients with Graves' ophthalmopathy using the indirect ELISA method. There was a significant difference in the levels of both IgG and IgA antibodies between the patients with Graves' ophthalmopathy and a control group (p < 0.001). IgA antibodies to eye muscle cytosol antigens were raised in 20 out of 29 patients with proptosis (class 3 ophthalmopathy), in comparison with 31 patients out of the total group of 60 with Graves' ophthalmopathy (p < 0.02). Anti-TSH receptor antibodies (TRAK) were not present in over half of the 31 patients with raised IgA antibodies to eye muscle antigens. However, a significant difference was found between the levels of IgG and IgA antibodies in the TRAK-negative patients (p < 0.05). These findings suggests that both IgG and IgA antibodies to eye muscle antigens might be important in the development of ophthalmopathy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1363165

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  3 in total

1.  Effect of radioiodine therapy on the presence of autoantibodies against human thyroid and eye muscle fractions.

Authors:  I Molnár; C Balázs
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

2.  IgA anti-eye muscle cytosol autoantibodies and the clinical stage in Graves' disease.

Authors:  I Molnár; C Balázs
Journal:  J Endocrinol Invest       Date:  1994-09       Impact factor: 4.256

3.  IgA autoantibodies against human eye muscle antigen detected by western blotting and immunohistochemical methods in Graves' disease.

Authors:  I Molnár; V Kaczur; A Boros; G Krajczár; C Balázs
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.